Anti-EAV Drug Discovery Products

Equine Arteritis Virus (EAV) is a member of the Arteriviridae family and the genus Alpharterivirus. This enveloped, positive-sense RNA virus is renowned for its impact on horses, causing Equine Viral Arteritis (EVA). With a genome comprising a single strand of RNA, EAV encodes both structural and non-structural proteins critical for its lifecycle. Seven structural proteins consist of the nucleocapsid protein N, the envelope proteins M and E, and the N-glycosylated membrane proteins GP2b, GP3, GP4, and GP5. The virus primarily infects horses, with stallions being more susceptible than mares. Cross-species transmission is limited to horses and related species. EAV infection can lead to a range of clinical manifestations, from respiratory distress to reproductive issues, making it a significant concern in the equine industry. The virus enters host cells through specific membrane receptors, initiating replication and leading to the characteristic symptoms. While EAV lacks a specific antiviral treatment, understanding its genome and proteins is crucial for developing effective preventive measures. As you delve into the intricate world of Equine Arteritis Virus, our virus antibody products are vital tools for your research.